Y-mAbs Therapeutics (NASDAQ:YMAB) Raised to “Strong-Buy” at Brookline Capital Management

Brookline Capital Management upgraded shares of Y-mAbs Therapeutics (NASDAQ:YMAB) to a strong-buy rating in a research note released on Wednesday morning,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Wedbush reiterated an “outperform” rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Tuesday, September 10th. Oppenheimer started coverage on Y-mAbs Therapeutics in a research report on Monday, November 18th. They set an “outperform” rating and a $23.00 target price for the company. Morgan Stanley lowered their price target on Y-mAbs Therapeutics from $12.00 to $11.00 and set an “underweight” rating on the stock in a report on Tuesday, August 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $20.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, September 9th. Finally, Canaccord Genuity Group reiterated a “buy” rating and set a $26.00 price objective on shares of Y-mAbs Therapeutics in a research report on Tuesday, August 13th. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $20.89.

Y-mAbs Therapeutics Stock Performance

NASDAQ YMAB opened at $10.54 on Wednesday. The business’s fifty day moving average is $13.24 and its 200 day moving average is $12.76. The company has a market capitalization of $472.09 million, a PE ratio of -19.52 and a beta of 0.61. Y-mAbs Therapeutics has a fifty-two week low of $6.09 and a fifty-two week high of $20.90.

Y-mAbs Therapeutics (NASDAQ:YMAB) last released its earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.02). The firm had revenue of $18.46 million during the quarter, compared to analysts’ expectations of $23.38 million. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. During the same period in the prior year, the company posted ($0.18) earnings per share. On average, sell-side analysts forecast that Y-mAbs Therapeutics will post -0.64 EPS for the current year.

Insider Transactions at Y-mAbs Therapeutics

In other news, insider Thomas Gad sold 30,000 shares of the company’s stock in a transaction dated Monday, September 16th. The shares were sold at an average price of $12.97, for a total transaction of $389,100.00. Following the sale, the insider now directly owns 67,681 shares in the company, valued at approximately $877,822.57. This represents a 30.71 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.50% of the company’s stock.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Squarepoint Ops LLC lifted its stake in shares of Y-mAbs Therapeutics by 143.4% during the 2nd quarter. Squarepoint Ops LLC now owns 126,389 shares of the company’s stock worth $1,527,000 after acquiring an additional 74,452 shares during the last quarter. SG Americas Securities LLC bought a new position in Y-mAbs Therapeutics in the third quarter worth approximately $178,000. Caligan Partners LP grew its position in shares of Y-mAbs Therapeutics by 105.3% during the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock worth $15,718,000 after buying an additional 613,175 shares in the last quarter. Principal Financial Group Inc. bought a new position in shares of Y-mAbs Therapeutics during the 3rd quarter worth $267,000. Finally, Millennium Management LLC increased its stake in shares of Y-mAbs Therapeutics by 23.8% during the second quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock valued at $4,225,000 after buying an additional 67,233 shares during the period. 70.85% of the stock is owned by institutional investors.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.